SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 11, 2018--Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Goldman Sachs 39th Annual Global Healthcare Conference, June 14, 2018, at 8:00 am PT.

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and the focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit  www.fiveprime.com or follow us on LinkedIn, Twitter and Facebook.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005946/en/

CONTACT: Five Prime Therapeutics, Inc.

Heather Rowe, 415-365-5737

Senior Director, Investor Relations and Corporate Communications

heather.rowe@fiveprime.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: Five Prime Therapeutics, Inc.

Copyright Business Wire 2018.

PUB: 06/11/2018 04:05 PM/DISC: 06/11/2018 04:05 PM

http://www.businesswire.com/news/home/20180611005946/en